^
Association details:
| Biomarker: | TNFRSF17 positive |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | Tecvayli (teclistamab-cqyv) (CD3 agonist, BCMA inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma
Published date:
09/21/2020
Excerpt:
Teclistamab also depleted BCMA+ cells in bone marrow samples from MM patients in an ex vivo assay with an average EC50 value of 1.7 nM. Under more physiological conditions using healthy human whole blood, teclistamab mediated dose-dependent lysis of H929 cells and activation of T cells.
DOI:
https://doi.org/10.1182/bloodadvances.2020002393
